

Ailiang Zeng

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8555326/ailiang-zeng-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

931
citations

14
h-index

22
g-index

22
ext. papers

1,193
ext. citations

7.9
avg, IF

4.38
L-index

#	Paper	IF	Citations
22	Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. <i>Molecular Cancer</i> , 2019 , 18, 71	42.1	210
21	Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 166	12.8	103
20	Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. <i>Cancer Letters</i> , 2018 , 436, 10-21	9.9	92
19	Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. <i>EBioMedicine</i> , 2019 , 42, 238-251	8.8	86
18	miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. <i>Neuro-Oncology</i> , 2017 , 19, 55-65	1	84
17	miR-129-5p targets Wnt5a to block PKC/ERK/NF- κ B and JNK pathways in glioblastoma. <i>Cell Death and Disease</i> , 2018 , 9, 394	9.8	62
16	IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. <i>Oncotarget</i> , 2015 , 6, 30232-8	3.3	53
15	H19 Functions as a Competing Endogenous RNA to Regulate EMT by Sponging miR-130a-3p in Glioma. <i>Cellular Physiology and Biochemistry</i> , 2018 , 50, 233-245	3.9	42
14	MicroRNA-141-3p promotes glioma cell growth and temozolomide resistance by directly targeting p53. <i>Oncotarget</i> , 2017 , 8, 71080-71094	3.3	34
13	Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma. <i>Oncogene</i> , 2019 , 38, 2706-2721	9.2	23
12	CircRNACCDC66 regulates cisplatin resistance in gastric cancer via the miR-618/BCL2 axis. <i>Biochemical and Biophysical Research Communications</i> , 2020 , 526, 713-720	3.4	22
11	S100A11 functions as novel oncogene in glioblastoma via S100A11/ANXA2/NF- κ B positive feedback loop. <i>Journal of Cellular and Molecular Medicine</i> , 2019 , 23, 6907-6918	5.6	19
10	The long noncoding RNA ZFAS1 promotes the progression of glioma by regulating the miR-150-5p/PLP2 axis. <i>Journal of Cellular Physiology</i> , 2020 , 235, 2937-2946	7	18
9	Fstl1 Promotes Glioma Growth Through the BMP4/Smad1/5/8 Signaling Pathway. <i>Cellular Physiology and Biochemistry</i> , 2017 , 44, 1616-1628	3.9	17
8	Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p. <i>Theranostics</i> , 2021 , 11, 1763-1779	12.1	13
7	miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas. <i>Oncolmmunology</i> , 2018 , 7, e1510277	7.2	12
6	Long non-coding RNA SNHG5 promotes glioma progression via miR-205/E2F3 axis. <i>Bioscience Reports</i> , 2019 , 39,	4.1	11

5	Genome-wide identification of epithelial-mesenchymal transition-associated microRNAs reveals novel targets for glioblastoma therapy. <i>Oncology Letters</i> , 2018 , 15, 7625-7630	2.6	9
4	Exosomes derived from microRNA-512-5p-transfected bone mesenchymal stem cells inhibit glioblastoma progression by targeting JAG1. <i>Aging</i> , 2021 , 13, 9911-9926	5.6	7
3	RelB, a good prognosis predictor, links cell-cycle and migration to glioma tumorigenesis. <i>Oncology Letters</i> , 2018 , 15, 4404-4410	2.6	5
2	Qki activates Srebp2-mediated cholesterol biosynthesis for maintenance of eye lens transparency. <i>Nature Communications</i> , 2021 , 12, 3005	17.4	5
1	Polycomb group expression signatures in the malignant progression of gliomas. <i>Oncology Letters</i> , 2017 , 13, 2583-2590	2.6	4